|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.88 USD | +6.62% |
|
+9.43% | -29.50% |
| 10/06 | EyePoint, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 11:20 AM | |
| 14/05 | EyePoint's late-stage eye drug trials to continue after safety panel review | RE |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 37 | +187.27% | 12 | ||||||
| 1,215.79 | +8.31% | 29 | ||||||
| 252.87 | +7.52% | 23 | ||||||
| 253.55 | +13.97% | 29 | ||||||
| 360.76 | +11.35% | 17 | ||||||
| 154.88 | +2.68% | 21 | ||||||
| 221.03 | +23.98% | 21 | ||||||
| 311.78 | +11.23% | 23 | ||||||
| 352.77 | +1.42% | 30 | ||||||
| 157.57 | +23.85% | 28 | ||||||
| 29.19 | +12.09% | 27 | ||||||
| 63.08 | +12.8% | 25 | ||||||
| 548.69 | +21.08% | 29 | ||||||
| 96.7 | +27.81% | 23 | ||||||
| 20.77 | +6.49% | 19 | ||||||
| 9,973.33 | +32.57% | 15 | ||||||
| 6,086.87 | +21.25% | 15 | ||||||
| 81.14 | +71.36% | 16 | ||||||
| 49.5 | +37.46% | 19 | ||||||
| 4.148 | +24.46% | 17 | ||||||
| Average | 1,013.57 | +27.95% | 22 | ||||||
| Weighted average by Cap. | 710.08 | +12.85% | 25 |
- Stock Market
- Stocks
- EYPT Stock
- Sector EyePoint, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition